ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0896

Screening of Lipids in Patients with Rheumatoid Arthritis: Academic Rheumatology Practice Quality Improvement Analysis

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 1020

Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0615

Semaphorin 5A Suppresses Ferroptosis Through Activation of PI3K-AKT-mTOR Signaling in Rheumatoid Arthritis

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0889

Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0960

Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0884

Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0883

Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0652

Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0799

Serum Laboratory Parameters of Hemophagocytic Lymphohistiocytosis Syndrome in Patients with Autoimmune Rheumatic Diseases Infected with SARS-CoV-2: A Retrospective Comparative Study

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0660

Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0616

Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0636

Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0929

Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0705

Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 1052

Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey

Systemic Sclerosis and Related Disorders – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].